Welcome to the Neuropsychiatric Drug Development Summit: Developing a New Wave of Clinically Efficacious Therapeutics for Neuropsychiatric Disorders

This last year has been a brutal reminder as to how crucial it is that we tackle the impending global mental health crisis and find a path towards successful neuropsychiatric drug development.

We are proud to be the industry’s definitive and unrivaled forum focused on encapsulating the recent clinical advances across this extremely arduous field.

This timely meeting provides a much-needed platform for industry and academic thought leaders to:

  • Investigate new treatment paradigms to support schizophrenia patients with Sunovion, Merck, Cerevel and BioXcel
  • Strive for useful biomarkers in clinical practice and explore novel electrophysiological biomarkers of synaptic plasticity in humans with Lundbeck, Daniel Javitt and Takeda
  • Hear patient-centric approaches towards developing efficacious and engaging digital therapeutics with Thomas Insel, MindMed
  • Decipher the recent hype in psychedelics by evaluating new data emerging on hallucinogens with Psilera, MAPS, Eleusis, ATAI and Perception Neuroscience
  • Discover the major advances in understanding neuroinflammation across CNS indications and how can we use this to help us further understand psychiatric conditions with Johnson & Johnson and Inmune Bio

Join over 80 of your peers to take a step closer towards your ambitious goal of drastically improving the lives of individuals living with neuropsychiatric disorders.

Expert Speaker Faculty:

Mark Varney

Chief Scientific Officer


Massimiliano Bianchi

Founder / President & CEO

Ulysses Neuroscience

Patricio O’Donnell

Executive Medical Director, Head of Neurocircuitry Modulation Biomarkers


Pradeep Nathan

Vice President & Head of Experimental Medicine & Professor of Neuroscience


Rick Doblin

Executive Director

Multidisciplinary Association for Psychedelic Studies

Heather Dworak

Senior Director, Clinical Research


Isabella Premoli

Imaging & Neurostimulation Specialist,


Jackie von Salm

Co-Founder, CSO

Psilera Bioscience

John Kealy


Ulysses Neuroscience

Srinivas Rao

Co-Founder & Chief Scientific Officer

Atai Life Sciences

Join Registered Companies From:

attending companies

Proud to Partner With:

Concert Pharmaceuticals

“Excellent conference with a very good and diverse set of speakers and topics”

Jim Cassella, Chief Development Officer, Concert Pharmaceuticals


“Very good conference”

Christopher Missling, President & Chief Executive Officer, Anavex Life Sciences Corp.

Other Events in the CNS Series: